Business
Media
Conferences
Publications
CME/CE
Resources
Subscribe

Erik Goluboff, MD, MBA, Tyra Biosciences, Inc.

Affiliations:

Tyra Biosciences, Inc.

Carlsbad, CA, USA

Articles by Erik Goluboff, MD, MBA, Tyra Biosciences, Inc.

Oral Selective FGFR3 Inhibition in Urothelial Carcinoma: Opportunities in Intermediate Risk Non-Muscle Invasive Bladder Cancer and Low Grade Upper Tract Urothelial Carcinoma

ByErik Goluboff, MD, MBA, Tyra Biosciences, Inc.

March 30th 2026

Latest Updated Articles

Trending on Urology Times

Matthew Truesdale, MD, on IsoPSA performance with and without mpMRI

Published VAPOR 2 data evaluate water vapor ablation for localized prostate cancer

Treatment Intensification in Metastatic Castration-Sensitive Prostate Cancer

The UroOnc Minute: Making Appointments More Effective, With David Canes, MD

From OR to office: How Break Wave changes urology practice workflow